JP2014510780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510780A5 JP2014510780A5 JP2014504392A JP2014504392A JP2014510780A5 JP 2014510780 A5 JP2014510780 A5 JP 2014510780A5 JP 2014504392 A JP2014504392 A JP 2014504392A JP 2014504392 A JP2014504392 A JP 2014504392A JP 2014510780 A5 JP2014510780 A5 JP 2014510780A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- sapacitabine
- decitabine
- weeks
- treatment cycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 claims 36
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 35
- 229960003603 decitabine Drugs 0.000 claims 35
- 229950006896 sapacitabine Drugs 0.000 claims 35
- 239000002207 metabolite Substances 0.000 claims 25
- 230000001988 toxicity Effects 0.000 claims 19
- 231100000419 toxicity Toxicity 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- DCYBPMFXJCWXNB-JWIUVKOKSA-N CNDAC Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 DCYBPMFXJCWXNB-JWIUVKOKSA-N 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1106339.3A GB201106339D0 (en) | 2011-04-14 | 2011-04-14 | Combination |
| GB1106339.3 | 2011-04-14 | ||
| GB1117693.0 | 2011-10-13 | ||
| GBGB1117693.0A GB201117693D0 (en) | 2011-10-13 | 2011-10-13 | Combination |
| GB1121105.9 | 2011-12-08 | ||
| GBGB1121105.9A GB201121105D0 (en) | 2011-12-08 | 2011-12-08 | Combination |
| PCT/GB2012/050815 WO2012140436A1 (en) | 2011-04-14 | 2012-04-13 | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510780A JP2014510780A (ja) | 2014-05-01 |
| JP2014510780A5 true JP2014510780A5 (enExample) | 2015-04-30 |
| JP6093755B2 JP6093755B2 (ja) | 2017-03-08 |
Family
ID=46022492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504392A Expired - Fee Related JP6093755B2 (ja) | 2011-04-14 | 2012-04-13 | 急性骨髄性白血病を治療するためのサパシタビンとデシタビンの組合せの投与計画 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10226478B2 (enExample) |
| EP (2) | EP2696878B1 (enExample) |
| JP (1) | JP6093755B2 (enExample) |
| ES (1) | ES2743691T3 (enExample) |
| HU (1) | HUE046177T2 (enExample) |
| PL (1) | PL2696878T3 (enExample) |
| WO (1) | WO2012140436A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046177T2 (hu) | 2011-04-14 | 2020-02-28 | Cyclacel Ltd | Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére |
| WO2013171473A1 (en) | 2012-05-15 | 2013-11-21 | Cyclacel Limited | Dosage regimen for sapacitabine and seliciclib |
| CN105960239A (zh) | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| WO2019081951A1 (en) | 2017-10-27 | 2019-05-02 | Cyclacel Limited | DOSAGE REGIME |
| WO2021079129A1 (en) | 2019-10-24 | 2021-04-29 | Cyclacel Limited | Dosing regimen |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2559917B2 (ja) | 1990-06-15 | 1996-12-04 | 三共株式会社 | ピリミジンヌクレオシド誘導体 |
| RU2085557C1 (ru) | 1991-09-30 | 1997-07-27 | Санкио Компани Лимитед | Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения |
| US5824984A (en) | 1997-03-31 | 1998-10-20 | Morrow; John A. | Portable electric wire cutter |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| US6835185B2 (en) | 1998-12-21 | 2004-12-28 | Micrus Corporation | Intravascular device deployment mechanism incorporating mechanical detachment |
| US6462063B1 (en) | 2000-02-04 | 2002-10-08 | Fibrogen, Inc. | C-proteinase inhibitors |
| US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| PY0111577A (es) | 2000-05-23 | 2017-01-02 | Idenix Cayman Ltd | Métodos y composiciones para el tratamiento del virus de la hepatitis c |
| AP2006003708A0 (en) | 2000-05-26 | 2006-08-31 | Idenix Cayman Ltd | Methods and compositions for treating flavivirusesand pestiviruses |
| WO2001097843A2 (en) | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| AU2002230385A1 (en) | 2000-09-25 | 2002-04-15 | Questcor Pharmaceuticals, Inc. | Peptide deformylase inhibitors |
| WO2002033128A2 (en) | 2000-10-18 | 2002-04-25 | Pharmasset Limited | Multiplex quantification of nucleic acids in diseased cells |
| JP2004533406A (ja) | 2000-10-18 | 2004-11-04 | フアーマセツト・リミテツド | ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド |
| WO2002046182A1 (en) | 2000-12-08 | 2002-06-13 | Bristol-Myers Squibb Pharma Company | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| JP3748536B2 (ja) | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
| US6908906B2 (en) | 2001-02-09 | 2005-06-21 | Sankyo Company, Limited | Crystalline forms of pyrimidine nucleoside derivative |
| US6676692B2 (en) | 2001-04-27 | 2004-01-13 | Intek Technology L.L.C. | Apparatus for delivering, repositioning and/or retrieving self-expanding stents |
| JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物 |
| WO2003039536A1 (en) | 2001-11-07 | 2003-05-15 | Yale University | Enhancement of taxane-based chemotherapy by a cdk1 antagonist |
| US7137993B2 (en) | 2001-12-03 | 2006-11-21 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
| US8383605B2 (en) | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| JP2006528697A (ja) | 2003-05-16 | 2006-12-21 | イデラ ファーマシューティカルズ インコーポレイテッド | イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置 |
| US20050014716A1 (en) | 2003-05-21 | 2005-01-20 | Wang Jin Wei | Pancreatic cancer treatment |
| GB0328180D0 (en) | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
| WO2006090931A1 (ja) | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の抗癌剤との新規併用 |
| US20060212898A1 (en) | 2005-03-17 | 2006-09-21 | Ryan Steelberg | System and method for broadcast target advertising |
| GB0523041D0 (en) | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| GB0526419D0 (en) | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
| GB0609530D0 (en) | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| WO2008132443A1 (en) | 2007-04-25 | 2008-11-06 | Cyclacel Limited | Use of sapacitabine to treat proliferative disease |
| US8124593B2 (en) | 2007-11-05 | 2012-02-28 | Cyclacel Limited | Methods of treatment using sapacitabine |
| CN101185629A (zh) | 2007-12-14 | 2008-05-28 | 山东蓝金生物工程有限公司 | 一种治疗实体肿瘤的地西他滨缓释剂 |
| GB0808357D0 (en) | 2008-05-08 | 2008-06-18 | Cyclacel Ltd | Process |
| KR101667641B1 (ko) | 2008-06-09 | 2016-10-20 | 싸이클라셀 리미티드 | 데시타빈 및 프로카인과 같은 ｄｎａ 메틸전이효소 저해제와 사팍시타빈 또는 ｃｎｄａｃ의 조합 |
| HUE046177T2 (hu) | 2011-04-14 | 2020-02-28 | Cyclacel Ltd | Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére |
-
2012
- 2012-04-13 HU HUE12717824A patent/HUE046177T2/hu unknown
- 2012-04-13 EP EP12717824.2A patent/EP2696878B1/en active Active
- 2012-04-13 JP JP2014504392A patent/JP6093755B2/ja not_active Expired - Fee Related
- 2012-04-13 US US14/111,430 patent/US10226478B2/en active Active
- 2012-04-13 PL PL12717824T patent/PL2696878T3/pl unknown
- 2012-04-13 WO PCT/GB2012/050815 patent/WO2012140436A1/en not_active Ceased
- 2012-04-13 ES ES12717824T patent/ES2743691T3/es active Active
- 2012-04-13 EP EP19176614.6A patent/EP3560501A1/en not_active Withdrawn
-
2019
- 2019-01-16 US US16/249,274 patent/US20190314396A1/en not_active Abandoned